Earnings Feed
Start Free
PTC THERAPEUTICS, INC.·4

Feb 19, 5:25 PM ET

Boulding Mark Elliott 4

Research Summary

AI-generated summary

Updated

PTC Therapeutics (PTCT) EVP & CLO Mark Boulding Exercises Options, Sells

What Happened

  • Mark Elliott Boulding, Executive VP and Chief Legal Officer of PTC Therapeutics, exercised 2,813 option-derived shares on 2026-02-17 at $25.69 per share (exercise cost $72,266) and then sold the acquired shares and additional shares in open-market transactions on 2026-02-17 and 2026-02-18. Total reported sale proceeds were $408,612 across the trades. These actions are sales (routine monetization), not outright purchases.

Key Details

  • Transaction dates and amounts:
    • 2026-02-17: Exercise (derivative conversion) 2,813 shares @ $25.69 — cost $72,266.
    • 2026-02-17: Open-market sale 2,811 shares @ $69.29 — proceeds $194,774 (weighted avg; trades ranged $68.84–$69.80).
    • 2026-02-17: Open-market sale 2 shares @ $70.13 — proceeds $140.
    • 2026-02-18: Open-market sale 3,081 shares @ $69.36 — proceeds $213,698.
    • Form also shows a $0 disposal entry for 2,813 derivative shares on 2026-02-17 (standard reporting when options are converted/exercised).
  • Total sale proceeds reported: $408,612; total exercise cost: $72,266.
  • Shares owned after the transactions: not specified in the provided filing excerpt.
  • Footnotes of note:
    • F1: Some sales were effected under a written Rule 10b5-1 trading plan adopted Dec 4, 2024.
    • F2: The $69.29 figure is a weighted average of multiple trades (range $68.84–$69.80).
    • F3: A portion of shares were automatically sold to satisfy tax withholding tied to RSU vesting (sell-to-cover).
    • F4: Options exercised were currently exercisable.
  • Filing was submitted Feb 19, 2026 for transactions reported on Feb 17–18, 2026 (no late-filing indication in provided data).

Context

  • This sequence reflects an option exercise followed by immediate or near-immediate open-market sales (a cashless exercise / sell-to-cover pattern). Some sales were executed under a pre-established 10b5-1 plan and some were automatic sell-to-cover actions to satisfy tax withholding on RSU vesting — both are routine mechanisms for insiders to meet tax obligations or diversify, and do not alone indicate management sentiment.